Table 1.
Type of glucosamine | N | Duration (month) | Health utility changes in the glucosamine group | Health utility changes in the Placebo group | |
---|---|---|---|---|---|
Giordano et al. [17] | pCGS | 60 | 3 | 0.135 | − 0.0742 |
Beaumont et al. [16] | pCGS | 210 | 6 | 0.0785 | 0.0315 |
Reginster et al. [14] | pCGS | 212 | 36 | 0.1606 | 0.1427 |
Pavelka et al. [15] | pCGS | 202 | 36 | 0.0487 | 0.0207 |
Houpt et al. [18] | Other form of glucosamine | 101 | 2 | 0.0293 | 0.0129 |
McAlindon et al. [19] | Other form of glucosamine | 205 | 3 | − 0.0465 | − 0.0339 |
Frestedt et al. [22] | Other form of glucosamine | 35 | 3 | 0.1629 | 0.0613 |
Chopra et al. [25] | Other form of glucosamine | 70 | 3 | 0.0016 | 0.1232 |
Cibere et al. [20] | Other form of glucosamine | 137 | 6 | 0.0096 | 0.0006 |
Clegg et al. [21] | Other form of glucosamine | 630 | 6 | 0.0242 | 0.0383 |